OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

Patents go via first filed, and OWCP filed 8 patents in 2014, so I'm not worried about their Multiple Myeloma, PTSD and Migraine pipelines.

The real reason de-scheduling will immediately benefit OWCP is because other companies will need to license OWCP's 3 delivery systems - creme, sublingual tablet, nasal spray - to pursue their own clinical trials. For several potential treatments, CBD can't pass through the liver. So ingestion is not an option.

Initially, not much money will come in from licensing tech during clinical trials, but longer term, once other companies have FDA approved drugs, OWCP would get a small percent of those billions of dollars of sales. Forever! Even the generic pharma co's will want OWCP patented delivery systems.

The genius of OWCP is that they've been in MMJ for years and they have multiple paths for revenue- sale of cremes, consulting to governments, licensing of delivery systems, and eventually sale of FDA approved treatments. The other MMJ companies I've look at only have 1 horse in the game. We have 4 or more!